FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083679963> ?p ?o ?g. }

• W2083679963 endingPage "750" @default.
• W2083679963 startingPage "744" @default.
• W2083679963 abstract "In Brief BACKGROUND The primary treatment for craniopharyngiomas is total excision, but recurrence is common. However, current knowledge on the mechanisms of recurrence is limited. OBJECTIVE We hypothesized that recurrence is linked to the angiogenesis of the tumor. Recurrent and nonrecurrent tumor samples were compared with regard to expression of angiogenesis-related factors and angiogenic capacity in a corneal angiogenesis model. METHODS Specimens of 4 recurrent and 6 nonrecurrent tumors were selected from 57 patients with adamantinomatous craniopharyngiomas. Sections were immunohistochemically stained with antibodies for vascular endothelial growth factor (VEGF), fibronectin, fibroblast growth factor (FGF)-2, platelet-derived growth factor (PDGF)-A, PDGF-B, platelet-derived growth factor receptor (PDGFR)-α, and PDGFR-β. Expression levels were graded using a 4-point scoring system and were compared. For corneal angiogenesis assay, tissue samples were inoculated in a micropocket created on the rat eye, and microvessels were counted on days 3, 5, 7, and 9 to evaluate angiogenic potential. RESULTS Expression of PDGFR-α and FGF-2 were significantly higher for recurrent tumors (P = .02 and P = .01). However, recurrent and nonrecurrent tumors did not differ in the expressions of other ligands and receptors (PDGF-A, PDGF-B, and PDGFR-β). Recurrent tumors displayed a higher angiogenic potential starting from the fifth day of corneal angiogenesis assay. CONCLUSION These findings suggest a relationship between recurrence of craniopharyngiomas and angiogenesis. New treatment modalities with selective PDGFR-α blockers may represent a novel and effective therapeutic option for the treatment of craniopharyngiomas. BACKGROUND: The primary treatment for craniopharyngiomas is total excision, but recurrence is common. However, current knowledge on the mechanisms of recurrence is limited. OBJECTIVE: We hypothesized that recurrence is linked to the angiogenesis of the tumor. Recurrent and nonrecurrent tumor samples were compared with regard to expression of angiogenesis-related factors and angiogenic capacity in a corneal angiogenesis model. METHODS: Specimens of 4 recurrent and 6 nonrecurrent tumors were selected from 57 patients with adamantinomatous craniopharyngiomas. Sections were immunohistochemically stained with antibodies for vascular endothelial growth factor (VEGF), fibronectin, fibroblast growth factor (FGF)-2, platelet-derived growth factor (PDGF)-A, PDGF-B, platelet-derived growth factor receptor (PDGFR)-α, and PDGFR-β. Expression levels were graded using a 4-point scoring system and were compared. For corneal angiogenesis assay, tissue samples were inoculated in a micropocket created on the rat eye, and microvessels were counted on days 3, 5, 7, and 9 to evaluate angiogenic potential. RESULTS: Expression of PDGFR-α and FGF-2 were significantly higher for recurrent tumors (P = .02 and P = .01). However, recurrent and nonrecurrent tumors did not differ in the expressions of other ligands and receptors (PDGF-A, PDGF-B, and PDGFR-β). Recurrent tumors displayed a higher angiogenic potential starting from the fifth day of corneal angiogenesis assay. CONCLUSION: These findings suggest a relationship between recurrence of craniopharyngiomas and angiogenesis. New treatment modalities with selective PDGFR-α blockers may represent a novel and effective therapeutic option for the treatment of craniopharyngiomas." @default.
• W2083679963 created "2016-06-24" @default.
• W2083679963 creator A5010548095 @default.
• W2083679963 creator A5012640515 @default.
• W2083679963 creator A5030255317 @default.
• W2083679963 creator A5041778364 @default.
• W2083679963 creator A5043513546 @default.
• W2083679963 creator A5062571375 @default.
• W2083679963 creator A5068668728 @default.
• W2083679963 creator A5080182731 @default.
• W2083679963 creator A5089452299 @default.
• W2083679963 date "2010-04-01" @default.
• W2083679963 modified "2023-10-15" @default.
• W2083679963 title "Expression of Angiogenic Factors in Craniopharyngiomas" @default.
• W2083679963 cites W11583091 @default.
• W2083679963 cites W1232974837 @default.
• W2083679963 cites W1550975546 @default.
• W2083679963 cites W1566059459 @default.
• W2083679963 cites W1783580437 @default.
• W2083679963 cites W1837651204 @default.
• W2083679963 cites W1972207253 @default.
• W2083679963 cites W1977130076 @default.
• W2083679963 cites W1978139448 @default.
• W2083679963 cites W1978396373 @default.
• W2083679963 cites W1988890429 @default.
• W2083679963 cites W1991568411 @default.
• W2083679963 cites W1994489529 @default.
• W2083679963 cites W1997016414 @default.
• W2083679963 cites W2008541191 @default.
• W2083679963 cites W2008689009 @default.
• W2083679963 cites W2019889754 @default.
• W2083679963 cites W2023220455 @default.
• W2083679963 cites W2032024195 @default.
• W2083679963 cites W2036109260 @default.
• W2083679963 cites W2042734556 @default.
• W2083679963 cites W2046848568 @default.
• W2083679963 cites W2047928566 @default.
• W2083679963 cites W2049128935 @default.
• W2083679963 cites W2058651524 @default.
• W2083679963 cites W2066374244 @default.
• W2083679963 cites W2075206548 @default.
• W2083679963 cites W2076654705 @default.
• W2083679963 cites W2078528534 @default.
• W2083679963 cites W2079415755 @default.
• W2083679963 cites W2088437608 @default.
• W2083679963 cites W2097441581 @default.
• W2083679963 cites W2098588666 @default.
• W2083679963 cites W2103051441 @default.
• W2083679963 cites W2124763505 @default.
• W2083679963 cites W2131862721 @default.
• W2083679963 cites W2137020659 @default.
• W2083679963 cites W2147859371 @default.
• W2083679963 cites W2153408124 @default.
• W2083679963 cites W2165853364 @default.
• W2083679963 cites W2169406351 @default.
• W2083679963 cites W2325527203 @default.
• W2083679963 cites W3026401196 @default.
• W2083679963 cites W4229850895 @default.
• W2083679963 cites W4236613971 @default.
• W2083679963 doi "https://doi.org/10.1227/01.neu.0000367553.65099.14" @default.
• W2083679963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20190664" @default.
• W2083679963 hasPublicationYear "2010" @default.
• W2083679963 type Work @default.
• W2083679963 sameAs 2083679963 @default.
• W2083679963 citedByCount "21" @default.
• W2083679963 countsByYear W20836799632012 @default.
• W2083679963 countsByYear W20836799632013 @default.
• W2083679963 countsByYear W20836799632016 @default.
• W2083679963 countsByYear W20836799632017 @default.
• W2083679963 countsByYear W20836799632018 @default.
• W2083679963 countsByYear W20836799632019 @default.
• W2083679963 countsByYear W20836799632022 @default.
• W2083679963 countsByYear W20836799632023 @default.
• W2083679963 crossrefType "journal-article" @default.
• W2083679963 hasAuthorship W2083679963A5010548095 @default.
• W2083679963 hasAuthorship W2083679963A5012640515 @default.
• W2083679963 hasAuthorship W2083679963A5030255317 @default.
• W2083679963 hasAuthorship W2083679963A5041778364 @default.
• W2083679963 hasAuthorship W2083679963A5043513546 @default.
• W2083679963 hasAuthorship W2083679963A5062571375 @default.
• W2083679963 hasAuthorship W2083679963A5068668728 @default.
• W2083679963 hasAuthorship W2083679963A5080182731 @default.
• W2083679963 hasAuthorship W2083679963A5089452299 @default.
• W2083679963 hasBestOaLocation W20836799631 @default.
• W2083679963 hasConcept C126322002 @default.
• W2083679963 hasConcept C142724271 @default.
• W2083679963 hasConcept C167734588 @default.
• W2083679963 hasConcept C170493617 @default.
• W2083679963 hasConcept C180361614 @default.
• W2083679963 hasConcept C2775960820 @default.
• W2083679963 hasConcept C2777025900 @default.
• W2083679963 hasConcept C2777587049 @default.
• W2083679963 hasConcept C2780394083 @default.
• W2083679963 hasConcept C2781294074 @default.
• W2083679963 hasConcept C502942594 @default.
• W2083679963 hasConcept C71924100 @default.
• W2083679963 hasConcept C74373430 @default.
• W2083679963 hasConceptScore W2083679963C126322002 @default.

• next